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2The current era of personalised medicine promises us medi-
ations tailored to the individual patient, minimising adverse ef-
ects, and maximising effectiveness. Yet, medication is only effec-
ive when taken as prescribed, which in the ‘real world’ turns out
o be a major challenge. Indeed, WHO and OECD estimate that
ne-out-of-two patients with chronic diseases does not use their
edication as prescribed [1,2]. In Europe alone, non-adherence
s estimated to annually contribute to the premature death of
00,000 patients and excess healthcare costs of €125 billion [2].
Contrary to what is often assumed, the non-adherence problem
s not exclusive to ‘real-world’ patients, but it also influences the
trictly regulated setting of clinical drug registration trials. Of ev-
ry hundred trial participants, four do not initiate a study drug.
ach study day, 10–12% does not take their medication while still
n treatment. In long-term studies, after one year, almost 40% of
rial participants have stopped taking their medication [3]. Novel
igital adherence monitoring devices may offer a solution for pa-
ients who tend to forget their medication and for trial regulators
o have granular data on the exact timing of medication use.
Recent publications highlight two important reasons why close
onitoring of adherence in drug registration trials is warranted.
irst, ignoring non-adherence could lead to underestimated drug
fficacy and safety. This may flaw regulators’ benefit-risk assess-
ent at time of drug registration [4]. Lower efficacy and artificially
mproved safety outcomes may result in approving higher doses
han appropriate, increasing healthcare costs and potentially avoid-
ble adverse reactions in the ‘real world’. The second issue is the
oss of statistical power of clinical trials caused by non-adherence.∗ Corresponding author at: University Medical Center Groniningen, Hanzeplein 1
Internal Postcode EB70), 9700 RB Groningen, the Netherlands.






589-5370/© 2019 Published by Elsevier Ltd. This is an open access article under the CCotably, a recent systematic review showed that undetected vari-
tions in adherence double the required number of participants of
evere asthma drug trials [5]. This leads to prolonged recruitment,
nefficient trials, longer time to market access, and higher costs.
In the last decades, trialists have been mostly dependent on in-
irect (e.g. pill counts) and subjective methods (e.g. patient self-
eport) to monitor medication adherence. Fortunately, the rise of
dvanced digital technologies currently enables more objective and
ranular adherence monitoring. Some examples of these advanced
echnologies include smart pill dispensers, electronic medication
ackaging, and smart inhaler add-ons. Some of these devices con-
ect to a mobile app that records when medication is administered
nd send reminders or motivational messages. These stand-alone
edical devices are usually developed independently of the drug
hey are monitoring and only assessed under medical device regu-
ations by so-called notified bodies.
More recent developments combine a drug with a smart ad-
erence monitoring tool, the so-called “drug-device combinations”.
ewly Food and Drug Administration (FDA) approved drug-device
ombinations include a smart insulin pen, a smart pill, and a
mart inhaler (Fig. 1 ). The first approved smart pill was a formula
f a digital period-size sensor with aripiprazole, an antipsychotic
gent. The same sensor is also combined in capsules with the oral
hemotherapeutic agent capecitabine [6]. The first approved smart
nhaler has a built-in sensor that measures inhaler adherence and
he adequacy of inspiratory flow. These integrated devices may
elp personalised disease management and could also be relevant
or doctors and payers to rule out non-adherence to first line ther-
pies before more expensive second line therapies, such as bio-
ogicals, are considered [7]. On the other hand, two key barriers
or wider smart device use in daily practice are their sustainability
e.g. battery waste, technical robustness) and system implementa-BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
4 T.R. Zijp, P.G.M. Mol and D.J. Touw et al. / EClinicalMedicine 15 (2019) 3–4


















[tion (e.g. privacy regulations, doctor and patient acceptability, and
affordability). Furthermore, it is important to define in which pa-
tient populations these drug-device combinations offer “value-for-
money”.
The aforementioned issues are typical real-world challenges,
but what about clinical drug trials? Currently, the FDA and EMA
do not enforce digital adherence monitoring in clinical trials. No-
tably, the International Council for Harmonization of Technical Re-
quirements for Pharmaceuticals for Human Use (ICH) has recently
revised the ICH-E9 guidance, where the term ‘estimand’ was in-
troduced [8]. Where previously the principal drug efficacy analysis
was based on the intention-to-treat principle, this revised global
regulatory guideline proposes a more precise estimate of treat-
ment effect that prospectively defines how to deal with e.g. pa-
tients discontinuing treatment. There is however no mentioning of
a distinction between non-initiators, poor adherers, or discontin-
ued patients [9]. This also hampers proper distinction between a
true ‘pharmacological’ non-responder and a simply non-adherent
patient. In the assessment of a drug’s efficacy, it is crucial to con-
sider this distinction before concluding that a drug is ineffective
based on a black box of actual medication use. We therefore be-
lieve formal guidance for clinical trials is needed on when, and
especially how, objective, digital, adherence monitoring should be
implemented. In our view, this would require joint efforts of regu-
lators (to enforce guideline changes), healthcare professionals and
trialists (to raise awareness on availability of adherence devices
and utilise them when deemed appropriate), and payers (to reim-
burse these technologies).
While personalised medicine is slowly becoming reality, this
cannot be implemented without proper insights into medication
adherence. It seems time to embrace the digital opportunities and
open up the adherence black box once and for all.
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